Vizsgálati helyszín
MercyOne Waterloo Cancer Center
Waterloo, Iowa 50702, Egyesült ÁllamokMég nincs intézményhez kötve
- 14futó vizsgálat
- 2lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 16 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis11 vizsgálat
- 2. fázis3 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz14 vizsgálat
- Lezárult2 vizsgálat
- Fő szponzor
- National Cancer Institute (NCI)13 vizsgálat
- SWOG Cancer Research Network2 vizsgálat
- Alliance for Clinical Trials in Oncology1 vizsgálat
Futó vizsgálatok
Fut, nem toboroz
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT04094688· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT03984448· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03793179· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
NCT03701282· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
NCT03737981· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02048813· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
S0820, Adenoma and Second Primary Prevention Trial
NCT01349881· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
NCT01522976· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
NCT01274338· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00602641· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
NCT00098475· 3. fázis· National Cancer Institute (NCI)· Forrás
Hibát jelzek